LUCIRA® by Pfizer

Pricing and Ordering Information

LUCIRA® by Pfizer COVID-19 & Flu Test

$83.90	$2013.60
per test*	24 test carton

***DISCOUNTS AVAILABLE FOR CONTRACTED CUSTOMERS**

For more information, contact Yasheka Sharma at Yasheka.Sharma@pfizer.com
Orders are placed through your wholesaler or distributor.

Pfizer prices are subject to change without notice. Price changes take effect immediately upon notification to customer. Pfizer policy is to communicate price changes at the close of business on the day prior to the effective date. Any change in market value, after a sale has been made, will not be recognized as a basis for a claim either by or against a customer. Prices are subject to all taxes, excises, or other charges levied by any government (national, state, or local) upon the sale, consumption, or use of the product. Pfizer reserves the right to limit orders by package within any given month based on an individual's purchase history. If an order above the allowance is received, Pfizer reserves the right to cancel the excess amount.

Please see all authorized device labeling at LUCIRAbyPfizer.com/hcp/labeling.

Reimbursement information

As a molecular, multiplex respiratory diagnostic test, LUCIRA® by Pfizer falls under the following CPT code, as defined by the American Medical Association:

87636: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique.

Emergency Use Authorization

The LUCIRA® by Pfizer COVID-19 & Flu Test has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and influenza B, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Indication For Use

The LUCIRA® by Pfizer COVID-19 & Flu Test is authorized for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A, and Influenza B viral RNA in anterior nasal swab specimens collected from individuals (2 years of age or older) who are suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider. Emergency use of this test is limited to authorized laboratories. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high, moderate, or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Only for National Account Director Use

Pfizer